Chick-Fil-A Has One Feature In Its Restaurants That McDonald's Has Been Getting Rid Of
Chick-Fil-A customers looking to pass down their fast food traditions to the younger generation can see which store has a playground via Chick-Fil-A's official website and app. This is easily done by selecting the playground filter when searching for nearby locations. Those concerned about potential germs in the play place can rest assured that Chick-Fil-A's playgrounds are sanitized nightly and disinfected bi-weekly via steam. Although not every Chick-Fil-A store has a playground, there may be alternatives. Some locations offer an indoor play experience like ball pits as well as kids' menu activities. Both of which are great ways to keep them entertained and engaged.
Read more: Ranking Fast Food Burgers From Worst To Best, According To Reddit
Perhaps the biggest reason that playgrounds are largely a thing of the past is due to increasing concerns about injury and pathogens. In 1995 and 1999, McDonald's agreed to pay two multi-million dollar settlements (one for $4 million in damages to the government, and another wherein the company would finance $5 million for a safety campaign) related to injuries at various playgrounds. As recently as 2019, the Consumer Product Safety Commission recalled certain McDonald's playground equipment after receiving 34 reports of related injuries. Turning to pathogens, a 2011 investigation conducted by university professor, Erin Carr-Jordan, uncovered that playgrounds at multiple fast food chains, contained strains of various dangerous pathogens that can cause food-borne illness, and even MRSA (via QSR Magazine).
It's possible that these multiple controversies caused many fast food restaurants to pull back from featuring playgrounds, but another major blow likely came from the effects of the COVID-19 pandemic. In 2020, McDonald's and other stores shuttered playgrounds to assist in measures taken to combat the spread of germs during the pandemic. In the end, many restaurants have seemed to shift focus away from reopening these playgrounds, favoring other marketing ventures. Interestingly, nostalgia still does play a large factor in many of these campaigns, such as the revitalization of McDonald's Szechuan Sauce. This isn't to say that fast food playgrounds have entirely disappeared. Aside from Chick-Fil-A, the World's Largest Entertainment McDonald's offers the likes of a full arcade and completely intact PlayPlace for kids to enjoy.
Want more food knowledge? Sign up to our free newsletter where we're helping thousands of foodies, like you, become culinary masters, one email at a time.
Read the original article on Food Republic.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Newsweek
an hour ago
- Newsweek
Puppy Found Unable To Breathe After Dog Attack Gets a Second Chance at Life
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Weighing just over 8 pounds, Eggroll the puppy was found wandering alone in a park in Seattle, Washington State. With severe facial injuries, it was clear she had been attacked. With fractured sinuses, a snout detached from her jaw and puncture marks throughout her face, it suggested she had been attacked by another dog. "She had fractured sinuses and her nose wasn't attached to her jaw and she had puncture wounds on her snout. It is like a dog bit her on the snout and lifted her nose off her jaw," Ellen Marett, executive director of Forgotten Dogs Rescue, told Newsweek. Shelter Animals Count says that there were 1,727,628 stray dogs taken in by rescues across the U.S. in 2023 and 1,686,545 in 2024. While this represents a slight decrease from 2023, it still reflects a persistent challenge in managing stray-dog populations, especially compared to the notable drop seen during the COVID-19 pandemic in 2020. Pictures of Eggroll after she was found with injuries that suggested she was attacked. Pictures of Eggroll after she was found with injuries that suggested she was attacked. Forgotten Dogs Rescue Eggroll was found wandering the park in late June and taken to Tri-City Animal Services before being transferred to Forgotten Dogs Rescue. There, Eggroll required surgery to reattach her snout. "They had to reattach her snout and, luckily, it has healed great," Marett said. "She had her surgery follow-up and got the all-clear." The surgery was funded thanks to popular dog social-media page weratedogs, who support shelter dogs with its charitable arm, 15/10 Foundation. After Eggroll's story was shared on Instagram, her story captured hearts, and her surgery was fully funded by the public in just 34 minutes. Pictures of Eggroll now, in a stroller, left, and being held outdoors, right. Pictures of Eggroll now, in a stroller, left, and being held outdoors, right. Forgotten Dogs Rescue "This breaks my heart," said one commenter, while another wrote: "You're going to be ok now Eggroll." While her breed remains a mystery, with guesses including Rottweiler or Doberman pinscher, Eggroll has now started to embrace puppyhood. "She is doing great, being a normal puppy. She can only play with soft, squishy toys for a while as things continue to heal, but we are happy to supply all the plushies she could possibly need," Marett said. "Now that she has gotten the all-clear, we can consider what else needs to be done to get her ready to be adopted into a wonderful forever home," Marett added. "We can't wait to see who the lucky folks are that adopt this pup. She is not only adorable but also sweet as pie." Do you have funny and adorable videos or pictures of your pet you want to share? Send them to life@ with some details about your best friend, and they could appear in our Pet of the Week lineup.
Epoch Times
an hour ago
- Epoch Times
NY Gov. Hochul Asks Supreme Court to Toss Lawsuit Over Covid-Era Vaccination Mandate
New York Gov. Kathy Hochul this week urged the Supreme Court to reject a lawsuit over the state's COVID-19-era vaccination mandate for health care workers. The New York State Department of Health issued an emergency rule in August 2021 requiring employers in the health care field to mandate COVID-19 vaccinations for their workers.
Yahoo
2 hours ago
- Yahoo
European regulatory authority adopts positive opinion for Novo Nordisk's Alhemo® (concizumab), recommending label expansion to treat haemophilia A and B without inhibitors
Pending European Commission (EC) approval, Alhemo® will become available to all adult and paediatric patients 12 years and older living with severe haemophilia A and moderate or severe haemophilia B without inhibitors. This positive opinion by the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) is based on results from the explorer8 trial, which showed that Alhemo® reduced spontaneous and traumatic bleeds for patients living with haemophilia A and B without inhibitors compared with no prophylaxis1. If approved by the EC, Alhemo®, with its pen-injector device, has the potential to be an efficacious and easy-to-use option for patients with haemophilia A and B without inhibitors1-3. Bagsværd, Denmark, 25 July 2025 – Novo Nordisk today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending an update of the Alhemo® (concizumab) label to include the treatment of severe haemophilia A and moderate or severe haemophilia B without inhibitors. 'If approved by the European Commission, this label update would extend Alhemo®'s convenient once-daily, under-the-skin administration to patients living with haemophilia without inhibitors, providing an efficacious prophylactic choice,' said Martin Holst Lange, executive vice president and head of Development at Novo Nordisk. 'Each person living with haemophilia has individual and evolving needs. With its user-friendly, pre-filled, portable pen, we believe that Alhemo® has the potential to offer even more patients an individualised and flexible treatment.' The positive CHMP opinion is based on the results from the phase 3 explorer8 trial, which met its primary endpoint. The results demonstrated that Alhemo® prophylaxis compared with no prophylaxis treatment led to an 86% reduction and 79% reduction in treated spontaneous and traumatic bleeds for patients living with haemophilia A without inhibitors and haemophilia B without inhibitors1, respectively. In this trial, Alhemo® showed a favourable safety profile in patients with haemophilia A and B without inhibitors1. Patient-Reported Outcome (PRO) data from the explorer8 study further indicated an improvement in health-related quality of life and reduction in treatment burden with Alhemo® treatment compared with no prophylaxis3. Specifically, trends favouring Alhemo® over prophylaxis were observed in the short-form health survey (SF-36v2) and Haemophilia Quality of Life Questionnaire for Adults (Haem-A-QoL) results, in patients with haemophilia A and haemophilia B; these included the change in 'bodily pain' and 'physical functioning' from baseline to week 24 in the survey, and the Haem-A-QoL 'total score' and the 'physical health' domain score3. Treatment preference results showed patients were also in favour of Alhemo® over no prophylaxis or previous treatment, with 70.9% of respondents indicating they prefer Alhemo® over their previous haemophilia treatment3. Following the positive opinion from the CHMP, Novo Nordisk expects the European Commission (EC) to approve the label update within approximately two months. About Alhemo® (concizumab)Alhemo® (concizumab) is an anti-tissue factor pathway inhibitor (TFPI), monoclonal antibody designed to block a protein in the body that stops blood from clotting. By blocking TFPI, Alhemo® ensures the production of thrombin, which helps to clot the blood and prevent bleeding4. Alhemo® is currently approved in Europe5, the United States6, India7, Brazil8 and Switzerland9 for the treatment of adolescents and adults (12 years or older) with haemophilia A and B with inhibitors. In Japan10 and Australia11, Alhemo® is currently approved for the treatment of adolescents and adults (12 years or older) with haemophilia A and B with and without inhibitors. In all approved countries, it is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes. About the explorer8 studyExplorer8 is a multicentre, open-label, randomised, phase 3a clinical trial aimed to establish the efficacy and safety profile of Alhemo® in adults and paediatric patients 12 years of age and older living with congenital severe haemophilia A or moderate or severe haemophilia B without inhibitors1,12. In explorer8, 148 patients were randomly assigned in a 1:2 ratio to receive no prophylaxis (arm 1, n=21) or Alhemo® prophylaxis (arm 2, n=42), and 85 were nonrandomly assigned to receive Alhemo® prophylaxis (arms 3 and 4). The initial loading dose of Alhemo® was 1 mg per kilogram of body weight, followed by 0.2 mg per kilogram daily, and potentially individualised on the basis of concizumab plasma concentration as measured at Week 41,12. The primary analysis was carried out when all patients in arms 1 and 2 completed at least 24 or 32 weeks, respectively, and compared the number of treated spontaneous and traumatic bleeding episodes, measured as annualised bleeding rate, between arms 1 and 21,12. Supportive secondary endpoints, such as percent of patients experiencing zero bleeds, are reported as descriptive results only1,12. The trial is still ongoing in the extension phase and is expected to complete in 20281,12. About haemophiliaHaemophilia is a rare inherited bleeding disorder that impairs the body's ability to make blood clots, a process needed to stop bleeding. It is estimated to affect approximately 1,125,000 people worldwide13. Due to the nature of haemophilia being an x-linked recessive disorder, it often presents differently in males compared with females, with roughly 88% of people diagnosed with haemophilia worldwide being male14,15. There are different types of haemophilia, which are characterised by the type of clotting factor protein that is defective or missing. Haemophilia A is caused by a missing or defective clotting Factor VIII (FVIII), and haemophilia B is caused by a missing or defective clotting Factor IX (FIX). About Novo NordiskNovo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 77,400 people in 80 countries and markets its products in around 170 countries. For more information, visit Facebook, Instagram, X, LinkedIn and YouTube. Contacts for further information Media: Ambre James-Brown +45 3079 9289abmo@ Liz Skrbkova (US)+1 609 917 0632lzsk@ Investors: Jacob Martin Wiborg Rode+45 3075 5956jrde@ Ida Schaap Melvold +45 3077 5649idmg@ Sina Meyer +45 3079 6656azey@ Max Ung+45 3077 6414 mxun@ Frederik Taylor Pitter +1 609 613 0568fptr@ _______________________References1. Chowdary P, Angchaisuksiri P, Apte S, et al. Concizumab prophylaxis in people with haemophilia A or haemophilia B without inhibitors (explorer8): a prospective, multicentre, open-label, randomised, phase 3a trial. Lancet Haematol. 2024;11:e891–e904. doi: 10.1016/S2352-3026(24)00307-7.2. Kahr Rasmussen N, Berg B, Christiansen ASL, et al. The Concizumab Pen-Injector is Easy to Use and Preferred by Hemophilia Patients and Caregivers: A Usability Study Assessing Pen-Injector Handling and Preference. Patient Prefer Adherence. 2024;18:1713–1727. doi: 10.2147/PPA.S470091.3. Angchaisuksiri P, von Mackensen S, Apte S, et al. Concizumab prophylaxis in people with hemophilia A or B without inhibitors: patient-reported outcome results from the phase 3 explorer8 study. Res Pract Thromb Haemost. 2025;9:102705. doi: 10.1016/ Matsushita T, Shapiro A, Abraham A, et al. Phase 3 Trial of Concizumab in Hemophilia with Inhibitors. N Engl J Med. 2023;389:783–794. doi: 10.1056/NEJMoa2216455.5. Alhemo® (concizumab): Summary of Product Characteristics. 2024. Available at: Last accessed: July 2025. 6. Alhemo® (concizumab-mtci): Prescribing Information. 2024. Available at: Last accessed: July 2025. 7. CDSCO. List of new drugs (r-DNA origin) approved for import and marketing in India during Jan, 2020 – Apr, 2025 Available at: Last accessed: July 2025. 8. Alhemo® (concizumab): Brazil Product Information. 2025. Available at: Last accessed: July 2025. 9. Alhemo® (concizumab): Switzerland Product Information. 2024. Available at: Last accessed: July 2025. 10. Alhemo® (concizumab): Japanese Product Information. Available at: Latest revision date: July 2025. 11. Alhemo® (concizumab): Therapeutic Goods Administration (TGA) Product Information. 2024. Available at: Last accessed: July 2025. 12. NCT04082429. Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia Without Inhibitors (explorer8). Available at: Last Accessed: July 2025. 13. Iorio A, Stonebraker JS, Chambost H, et al. Establishing the Prevalence and Prevalence at Birth of Hemophilia in Males: A Meta-analytic Approach Using National Registries. Ann Intern Med. 2019;171:540–546. doi: 10.7326/M19-1208.14. Centers for Disease Control and Prevention. About Hemophilia. Available at: Last accessed: July 2025. 15. Statista. Distribution of people with bleeding disorders worldwide in 2020, by gender. Available at: Last accessed: July 2025. Attachment PR250725-Alhemo-CHMP-Positive-OpinionSign in to access your portfolio
